PMD-026 for Breast Cancer
(Dauntless-1 Trial)
Trial Summary
What is the purpose of this trial?
The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer. PMD-026 is a targeted oral agent designed to kill tumor cells in metastatic breast cancer.
Will I have to stop taking my current medications?
The trial requires that you stop endocrine therapy at least 15 days before starting PMD-026. Other medications may need to be stopped if they fall under the exclusion criteria, such as recent chemotherapy or investigational therapy.
Eligibility Criteria
Adults with metastatic breast cancer, specifically triple-negative type that's worsened after standard treatments. Participants must have acceptable organ function and blood counts, not be pregnant or breastfeeding, agree to use contraception, and can't have certain infections or uncontrolled high blood pressure.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive daily dosing of PMD-026 in combination with fulvestrant according to the package insert
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term follow-up
Participants are monitored for overall survival and progression-free survival
Treatment Details
Interventions
- PMD-026
Find a Clinic Near You
Who Is Running the Clinical Trial?
Phoenix Molecular Designs
Lead Sponsor